Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma

Chris Labaki; Renee Maria Saliby; Ziad Bakouny; Eddy Saad; Karl Semaan; Marc Eid; Aly-Khan Lalani; Toni K Choueiri; David A Braun

doi:10.1016/j.hoc.2023.05.021

Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma

Hematol Oncol Clin North Am. 2023 Oct;37(5):937-942. doi: 10.1016/j.hoc.2023.05.021. Epub 2023 Jul 3.

Authors

Chris Labaki¹, Renee Maria Saliby², Ziad Bakouny³, Eddy Saad², Karl Semaan², Marc Eid², Aly-Khan Lalani⁴, Toni K Choueiri², David A Braun⁵

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: chris_labaki@dfci.harvard.edu.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
⁴ Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
⁵ Center of Molecular and Cellular Oncology (CMCO), Yale School of Medicine, New Haven, CT, USA.

PMID: 37407357
DOI: 10.1016/j.hoc.2023.05.021

Abstract

Patients with metastatic clear cell renal cell carcinoma (mccRCC) experience highly heterogeneous outcomes when treated with standard-of-care systemic regimens. Therefore, valid biomarkers are needed to predict the clinical response to these therapies and help guide management. In this review, the authors outline relevant and promising biomarkers for patients with mccRCC receiving systemic therapies, with a focus on immunotherapy-based regimens.

Keywords: Biomarkers; Immunotherapy; Renal cell carcinoma; Systemic therapy; Targeted therapy.

Publication types

Review

MeSH terms

Biomarkers
Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / pathology
Humans
Immunotherapy
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / pathology

Substances

Biomarkers

Supplementary concepts

Clear-cell metastatic renal cell carcinoma